Saul Yedgar
Corporate Officer/Principal bei The Hebrew University of Jerusalem
Profil
Saul Yedgar is a Professor-Emeritus at The Hebrew University of Jerusalem, where he has been employed since 1982.
He previously worked as the Chief Scientific Officer at Celsus Therapeutics Plc from 2005 to 2011.
Prior to that, he held positions as a Principal at the National Institutes of Health and Institut Curie.
Yedgar received his undergraduate degree from Bar-Ilan University and his doctorate from The Hebrew University of Jerusalem in 1977.
Aktive Positionen von Saul Yedgar
Unternehmen | Position | Beginn |
---|---|---|
The Hebrew University of Jerusalem | Corporate Officer/Principal | 01.01.1982 |
Ehemalige bekannte Positionen von Saul Yedgar
Unternehmen | Position | Ende |
---|---|---|
Institut Curie
Institut Curie Miscellaneous Commercial ServicesCommercial Services Institut Curie engages as a non-profit foundation. It operates a research center on biophysics, cell biology, and oncology and a hospital specialized in treatment of cancer. The company was founded in 1909 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Celsus Therapeutics Plc
Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Saul Yedgar
The Hebrew University of Jerusalem | Doctorate Degree |
Bar-Ilan University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Celsus Therapeutics Plc
Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Institut Curie
Institut Curie Miscellaneous Commercial ServicesCommercial Services Institut Curie engages as a non-profit foundation. It operates a research center on biophysics, cell biology, and oncology and a hospital specialized in treatment of cancer. The company was founded in 1909 and is headquartered in Paris, France. | Commercial Services |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |